Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis
Authors:
- Faizan AhmedFAFaizan Ahmed
- Saifullah KhanSKSaifullah Khan
- Madeeha ShafqatMSMadeeha Shafqat
- Najam GoharNGNajam Gohar
- Muhammad HassanMHMuhammad Hassan
- Muhammad HussainMHMuhammad Hussain
- Haris Bin TahirHTHaris Bin Tahir
- Tehmasp Rehman MirzaTMTehmasp Rehman Mirza
- Muhammad AbdullahMAMuhammad Abdullah
- Syed Muhammad Murtaza IshaqSISyed Muhammad Murtaza Ishaq
- Haider Hussain ShahHSHaider Hussain Shah
- Mohammad HamzaMHMohammad Hamza
Open Access
- 23 May 2026
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (6) , 222
Abstract
Background: Coronary artery disease (CAD) and heart failure with preserved ejection fraction (HFpEF) are major causes of morbidity and mortality. Systemic inflammation contributes to both, suggesting potential benefit from colchicine, though data in CAD-HFpEF are limited. Methods: We conducted a real-world study using the TriNetX Research Network, identifying 480,434 adults with CAD and HFpEF. Patients were categorized as colchicine users (n = 30,254) or non-users (n = 450,180). One-to-one propensity score matching yielded 28,941 patients per group. The primary outcome was a composite of acute myocardial infarction, stroke, all-cause mortality, and acute heart failure. Secondary outcomes included individual components, hospitalizations, atrial fibrillation, and gastrointestinal events, assessed at 1- and 3-year follow-up. Results: At 1 year, the primary outcome occurred in 16.9% of the colchicine group versus 19.8% of non-users (HR: 0.86, 95% CI: 0.81–0.91; p < 0.001). All-cause mortality was 11.4% versus 14.5% (HR: 0.77, 95% CI: 0.73–0.80; p < 0.001). At 3 years, the primary outcome occurred in 34.2% versus 39.7% (HR: 0.88, 95% CI: 0.85–0.92; p < 0.001), with acute heart failure slightly higher in the colchicine group (27.5% vs. 26.5%; HR: 1.04, 95% CI: 1.01–1.08; p = 0.009). Stroke was modestly reduced (HR: 0.93, 95% CI: 0.88–0.99; p = 0.014). No significant differences were seen in all-cause hospitalization, atrial fibrillation, or gastrointestinal events. Conclusions: In patients with CAD and HFpEF, colchicine was associated with lower short- and medium-term risk of composite cardiovascular events and mortality, with modest attenuation over time, suggesting early time-dependent association rather than sustained structural effects. Prospective randomized trials are warranted.Keywords
This publication has 21 references indexed in Scilit:
- Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOTCurrent Atherosclerosis Reports, 2026
- Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarctionAmerican Heart Journal, 2024
- Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trialOpen Heart, 2023
- Colchicine alleviates inflammation and improves diastolic dysfunction in heart failure rats with preserved ejection fractionEuropean Journal of Pharmacology, 2022
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic targetHeart Failure Reviews, 2013
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Evolving Approaches to the Management of Heart Failure with Preserved Ejection Fraction in Patients with Coronary Artery DiseaseCurrent Treatment Options in Cardiovascular Medicine, 2010